Oaktree Acquisition Corp. III Life Sciences (OACC) Long-Term Investments (2024 - 2026)
Oaktree Acquisition Corp. III Life Sciences filings provide 3 years of Long-Term Investments readings, the most recent being $203.4 million for Q1 2026.
- Quarterly Long-Term Investments rose 3.95% to $203.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $203.4 million through Mar 2026, up 3.95% year-over-year, with the annual reading at $201.6 million for FY2025, 4.12% up from the prior year.
- Long-Term Investments hit $203.4 million in Q1 2026 for Oaktree Acquisition Corp. III Life Sciences, up from $201.6 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $203.4 million in Q1 2026 and bottomed at $193.6 million in Q4 2024.
- Average Long-Term Investments over 3 years is $198.6 million, with a median of $198.7 million recorded in 2025.
- The largest annual shift saw Long-Term Investments increased 4.12% in 2025 before it grew 3.95% in 2026.
- Oaktree Acquisition Corp. III Life Sciences' Long-Term Investments stood at $193.6 million in 2024, then increased by 4.12% to $201.6 million in 2025, then rose by 0.92% to $203.4 million in 2026.
- Per Business Quant, the three most recent readings for OACC's Long-Term Investments are $203.4 million (Q1 2026), $201.6 million (Q4 2025), and $199.8 million (Q3 2025).